Use of Febuxostat in Hyperuricemia Among Hemodialysis Patients

Hyperuricemia is not infrequently encountered among hemodialysis patients. However, there is no clear data about use of febuxostat among hemodialysis patients, apart from very small case series. The aim of this study is to investigate the efficacy of using febuxostat for the treatment of Hyperuricemia among hemodialysis patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hyperuricemia Hemodialysis Complication Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

19 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age above 18 years
Hemodialysis patient
Hyperuricemia (Uric acid level above 6.0 mg/dL in females and 7.0 mg/dL in males)

Exclusion criteria

Patient currently and/or recently received drugs for hyperuricemia within the last three months
Patient had recent (within 3 months) change of erythropoiesis stimulating drugs or other drug known to increase uric acid e.g furosemide

Treatment and study plan

Febuxostat 40 milligramsTablet

Drug

Febuxostat 40 milligramsTablet every other day for 3 months

Primary outcomes

Change in serum uric acid

Time frame: at three months of Febuxostat 40 milligrams Tablet therapy

Change in serum uric acid after 3 months of Febuxostat 40 milligrams Tablet therapy

Sponsors and collaborators

Lead sponsor

Benha University

Other

Collaborators

New Jeddah Clinic Hospital

Registry information

Important dates

Study start: 2017
Primary completion: 2017
Study completion: 2017
First posted: May 11, 2017
Registry last updated: May 11, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed